Avacta Group files patent for extended circulating serum half-life therapeutic conjugates

Discover Avacta Group's groundbreaking patent for therapeutic conjugates with extended half-life, targeting improved efficacy in treating diseases like cancer. Learn more about this innovative approach now!

Mar 7, 2024 - 18:00

Discover Avacta Group's groundbreaking patent for therapeutic conjugates with extended half-life, targeting improved efficacy in treating diseases like cancer. Learn more about this innovative approach now!

Read the original article

Tags:

Previous Article

J&J seeks EU approval for new Darzalex multiple myeloma indication

Gilead Explores Triple-Target T-Cell Engagers in over $1.5B Merus Partnership

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Merck to invest €300m in South Korean bioprocessing centre

Merck to invest €300m in South Korean bioprocessing centre

Mar 22, 2024

Opinion: I declined to share my medical data with advertisers at my doctor’s office. One company claimed otherwise

Opinion: I declined to share my medical data with adver...

Apr 7, 2023

STAT+: Pharmalittle: Sanders wants to replace drug patents with prizes for innovation; FDA approves an anthrax vaccine

STAT+: Pharmalittle: Sanders wants to replace drug pate...

Jul 22, 2023